In 2003, a clinical trial demonstrated prolonged survival of colorectal cancer patients in combination regimes with humanized neutralizing antibodies (bevacizumab, approved by FDA 2005) targeting vascular endothelial growth factor (VEGF), providing proof-of-concept of the successful use of anti-angiogenic therapies in oncology. This evidence concerns the gene VEGFA and colorectal cancer.